: Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rally
MarketWatch
MARCH 24, 2023
IOVA on Friday said it had completed its rolling biologics license application submission to the U.S. Food and Drug Administration for lifileucel — a therapy intended to combat advanced melanoma in some cases. Biotech cancer-treatment developer Iovance Biotherapeutics Inc.
Let's personalize your content